SpringerLink
Log in

Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling

1 Week On/1 Week Off

  • Clinical Pharmacokinetics
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: This study investigated the pharmacokinetics of tretinoin during alternating cycles of 1 week of tretinoin treatment and 1 week drug-free in patients with Ph1+ chronic myelogenous leukaemia (CML) in the chronic phase.

Patients: Eighteen patients with CML were treated with tretinoin 80 mg/m2/day (in two divided doses) for 7 consecutive days every other week (one cycle = 1 week on/1 week off).

Results: Body systemic exposure to tretinoin as determined by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from (mean ± SD) 678.3 ± 498.1 to 258.7 ± 272.4 μg/L·h. In about 40% of the patients the decline in plasma concentrations was ≥80%, while 17% of the population did not experience any decline. On day 7 of cycle 1, the mean apparent oral clearance (CL/F) was 2.6 times the corresponding value on day 1. After 1 week without tretinoin, the mean AUC on day 1 of cycle 2 was lower (down 15%) but not statistically different from the corresponding value observed on day 1 of cycle 1; 62% of patients showed an increase in the AUC, which was 40% higher than the corresponding value on day 7 of cycle 1. On day 1 of cycle 6, the AUC and CL/F of tretinoin during a dosage interval were not statistically different from those observed on day 1 of cycle 1 and cycle 2. On all occasions the peak plasma concentration (Cmax) was strongly correlated to the corresponding AUC. No significant change in the time to observed Cmax (tmax) and in the elimination half-life (t½) was observed during the whole study. These results confirmed that the metabolism of tretinoin is rapidly up-regulated in CML patients, with significant declines in plasma drug exposure during the first week of drug administration. After tretinoin was discontinued, a return to the non-induced state followed a mean time-cycle similar to the induction. The strong decrease in the apparent oral drug clearance and the absence of significant variations in the drug half-life demonstrated that the presystemic extraction of tretinoin is the main cause of the marked decline in plasma drug exposure.

Conclusion: The favourable pharmacokinetic profile of tretinoin obtained by an intermittent regimen, 1 week on/1 week off therapy (vs continuous administration), suggests that such a therapeutic schedule is the most appropriate for the assessment of clinical efficacy in those pathologies in which its use is suitable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sporn MB, Roberts AB, Goodman DS. The retinoids: biology, chemistry and medicine. 2nd ed. New York: RavenPressLtd, 1994

    Google Scholar 

  2. Hill DL. Retinoids and cancer prevention. Annu Rev Nutr 1992; 12: 161–81

    Article  PubMed  CAS  Google Scholar 

  3. Sacchi S, Russo D, Avvisati G, et al. All-trans retinoic acid in hematological malignancies, an update. Haematologica 1997; 82(1): 106–21

    PubMed  CAS  Google Scholar 

  4. Warrel RP, Frankel Jr RP, Miller Jr WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin. N Engl J Med 1991; 324(20): 1385–93

    Article  Google Scholar 

  5. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994; 120: 278–86

    PubMed  CAS  Google Scholar 

  6. Gillis JC, Goa KL. Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukemia. Drugs 1995; 50(5): 897–923

    Article  PubMed  CAS  Google Scholar 

  7. Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175–81

    PubMed  CAS  Google Scholar 

  8. Cornic M, Delva L, Castaigne S, et al. In vitro all-trans retinoic acid sensitivity and cellular retinoic acid binding protein levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994; 8: 914–7

    PubMed  CAS  Google Scholar 

  9. Warrell RP. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood 1993; 82(7): 1949–53

    PubMed  CAS  Google Scholar 

  10. Muindi JRF, Young CW, Warrell RP. Clinical pharmacology of all-trans-retinoic acid. Leukemia 1994; 8: 1807–12

    PubMed  CAS  Google Scholar 

  11. Adamson PC. Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia, Semin Hematol 1994; 31(5): 14–7

    PubMed  CAS  Google Scholar 

  12. Adamson PC. Clinical and pharmacokinetic studies of all-trans retinoic acid in pediatric patients with cancer. Leukemia 1994; 8(11): 1813–6

    PubMed  CAS  Google Scholar 

  13. Regazzi BM, Iacona I, Gervasutti C, et al. Clinical pharmacokinetics of tretinoin. Clin Pharmacokinet 1997; 32(5): 382–402

    Article  PubMed  CAS  Google Scholar 

  14. Trump DL, Smith DC, Stiff D, et al. A phase II trial of all-trans retinoic acid in hormone refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 1997; 39(4): 349–56

    Article  PubMed  CAS  Google Scholar 

  15. Muindi J, Frankel SR, Miller WH, et al. Continuous treatment with all-trans retinoic acid results in a progressive decrease in plasma concentrations: implications for relapse and retinoid ‘resistance’ in acute promyelocytic leukemia. Blood 1992; 79: 299–303

    PubMed  CAS  Google Scholar 

  16. Agadir A, Cornic M, Lefebvre P, et al. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biological response relationship. J Clin Oncol 1995; 13(10): 2517–23

    PubMed  CAS  Google Scholar 

  17. Adamson PC, Boylan JF, Balis FM, et al. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein Cancer Res 1993; 53: 472–6

    CAS  Google Scholar 

  18. Cornic M, Delva L, Guidez F, et al. Induction of retinoic acid- binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992; 52: 3329–34

    PubMed  CAS  Google Scholar 

  19. Wadler S, Schwartz EL, Haynes H, et al. All-trans retinoic acid and interferon-ot-2a in patients with metastatic or recurrent carcinoma of the uterine cervix. Cancer 1997; 79(8): 1574–80

    Article  PubMed  CAS  Google Scholar 

  20. Sutton LM, Warmuth MA, Petros WP, et al. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol 1997; 40: 335–41

    Article  PubMed  CAS  Google Scholar 

  21. Adamson PC, Bailey J, Pluda J, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995; 13: 1238–40

    PubMed  CAS  Google Scholar 

  22. Lee JS, Newman RA, Lippman SM, et al. Phase I evaluation of all-trans retinoic acid with and without ketokonazole in adults with solid tumors. J Clin Oncol 1995; 13(6) 1501–8

    PubMed  CAS  Google Scholar 

  23. Toma S, Iacona I, Palumbo R, et al. Modulation of all-trans retinoic acid administered on intermittent schedule by α-interferon 2a in a patient with AIDS-related Kaposi's sarcoma. AIDS 1996; 10(9): 1049–50

    Article  PubMed  CAS  Google Scholar 

  24. Kizaki M, Ueno H, Yamazoe Y, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996; 87(2): 725–33

    PubMed  CAS  Google Scholar 

  25. Mehta K, Sadeghi T, McQueen T, et al. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans retinoic acid. Leukemia Res 1994; 18(8): 587–96

    Article  CAS  Google Scholar 

  26. Barua AB, Barres RO, Olson JA. Characterization of retinyl β-glucuronide in human blood. Am J Clin Nutr 1989; 50: 370–4

    PubMed  CAS  Google Scholar 

  27. Sacchi S, Regazzi MB, Awisati G, et al. Phase I/II study of the biological activity of all-trans retinoic acid in patients with Ph1 + chronic myeloid leukemia [abstract 3532]. Blood 1996; 88(10 Suppl. 1): 201b

    Google Scholar 

  28. Adamson PC, Pitot HC, Balis F, et al. Variability in the oral bioavailability of all-trans retinoic acid. J Natl Cancer Inst 1993; 85: 993–6

    Article  PubMed  CAS  Google Scholar 

  29. Fiorella PD, Napoli JL. Microsomal retinoic acid metabolism. J Biol Chem 1994; 269: 10538–44

    PubMed  CAS  Google Scholar 

  30. Data on file, F. Hoffmann-La Roche, Basel, Switzerland

  31. Rowland M, Tozer T. Clinical pharmacokinetics, concepts and applications. 1st ed. Philadelphia, Lea &Febiger, 1980: 138–50

    Google Scholar 

  32. Cullum ME, Zile MH. Metabolism of all-trans retinoic acid and all-trans retinyl acetate. J Biol Chem 1985; 260: 305–12

    Google Scholar 

  33. Davies DS, Ilett KF, George CF. Drug metabolism by intestinal mucosa. In: Prescott LF, Nimmo WS, editors. Drug absorption. The Proceedings of the International Conference on Drug Absorption, Edinburgh, September 1979. Balgowlah, Australia: ADIS Press, 1979: 73–9

    Google Scholar 

  34. el Mansouri S, Tod M, Leclerq M, et al. Time and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab Dispos 1995; 23(2): 227–31

    PubMed  Google Scholar 

  35. Roberts AB, Nichols MD, Newton DL, et al. In vitro metabolism of retinoic acid in hamster intestine and liver. J Biol Chem 1979; 254: 6296–302

    PubMed  CAS  Google Scholar 

  36. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735–8

    Article  PubMed  CAS  Google Scholar 

  37. Benet LZ. Efflux proteins and drug metabolism. Eur J Pharmaceut Sci 1997; 5Suppl. 2: S11

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gruppo Ematologico Retinoidi (GER), Milano, Italy

    Mario B. Regazzi, D. Russo, S. Sacchi, G. Visani, M. Lazzarino, G. Avvisati, P. G. Pelicci, G. Dastoli & C. Grandi

  2. Dipartimento di Farmacologia, IRCCS — Policlinico S. Matteo, Pavia, Italy

    I. Iacona, S. Spreafico & E. Guerra

  3. Clinica Ematologica, Policlinico Universitario, Udine, Italy

    R. Grattoni

  4. Clinica Ematologica Dell'Università di Siena, Siena, Italy

    P. Galieni

  5. Clinica Ematologica, Università di Ancona, Ancona, Italy

    S. Rupoli

  6. Istituto di Scienze Mediche, Policlinico Universitario di Milano, Milano, Italy

    A. M. Maiolo

  7. Istituto di Medicina Interna e Scienze Oncologiche, Università di Perugia, Perugia, Italy

    A. M. Liberati

Authors
  1. Mario B. Regazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Iacona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Sacchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Visani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Lazzarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Avvisati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. G. Pelicci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Dastoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Grandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Spreafico
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R. Grattoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P. Galieni
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S. Rupoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A. M. Maiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E. Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A. M. Liberati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario B. Regazzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Regazzi, M.B., Russo, D., Iacona, I. et al. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling. Clin. Drug Investig. 16, 25–33 (1998). https://doi.org/10.2165/00044011-199816010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199816010-00004

Keywords

Search

Navigation